Nasdaq · Biotech stocks database
RGEN (Repligen Corporation) stock: $173.49, $11.09B market cap, $863.0M cash, $10.78B EV, $11.73B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs – including monoclonal antibodies (“mAbs”) and mAb derivatives like antibody drug conjugates, recombinant proteins, RNA-based therapeutics and vaccines and cell and gene therapies (“C>”) – that are improving human health worldwide.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $863.0M |
|---|---|
| Debt | $555.6M |
| Net cash | $307.4M |
| Enterprise value | $10,782.7M |
| Basic shares | 63.9M shares |
| Fully diluted shares | 67.6M shares |
| Fully diluted market cap | $11,728.9M |
| Cash per share | $13.50 |
| Quarterly burn | +$32.8M generated |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Cap table as of 2025-12-31.
Loading RGEN daily closes…